

# Ana Elisa Lohmann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7501145/publications.pdf>

Version: 2024-02-01

19  
papers

298  
citations

1040056

9  
h-index

888059

17  
g-index

19  
all docs

19  
docs citations

19  
times ranked

607  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Futility of Futility Analyses in Adjuvant Trials in Hormone Receptor Positive Breast Cancer. Journal of the National Cancer Institute, 2022, , .	6.3	0
2	Obesity and Breast Cancer: Expanding the Hypothesis Space. Journal of the National Cancer Institute, 2021, 113, 107-108.	6.3	2
3	Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. Journal of the National Cancer Institute, 2021, 113, 1465-1475.	6.3	50
4	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
5	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
6	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast, 2019, 48, 17-23.	2.2	73
7	Normal Weight Adiposity and Postmenopausal Breast Cancer Risk. JAMA Oncology, 2019, 5, 150.	7.1	7
8	Association of obesity with breast cancer outcome in relation to cancer subtypes.. Journal of Clinical Oncology, 2019, 37, 11557-11557.	1.6	1
9	The effect of metformin on sex hormones in non-diabetic breast cancer patients in CCTG MA.32: A Phase III randomized adjuvant trial of metformin versus placebo in addition to standard therapy.. Journal of Clinical Oncology, 2019, 37, 529-529.	1.6	3
10	Novel Insights Into the Impact of Lifestyle-Based Weight Loss and Metformin on Obesity-Associated Biomarkers in Breast Cancer. Journal of the National Cancer Institute, 2018, 110, 1161-1162.	6.3	2
11	Association of Metabolic, Inflammatory, and Tumor Markers With Circulating Tumor Cells in Metastatic Breast Cancer. JNCI Cancer Spectrum, 2018, 2, pky028.	2.9	10
12	Metabolic factors, anthropometric measures, diet, and physical activity in long-term breast cancer survivors: change from diagnosis and comparison to non-breast cancer controls. Breast Cancer Research and Treatment, 2017, 164, 451-460.	2.5	15
13	Effects of metformin versus placebo on vitamin B12 metabolism in non-diabetic breast cancer patients in CCTG MA.32. Breast Cancer Research and Treatment, 2017, 164, 371-378.	2.5	9
14	Moving forward with obesity research in breast cancer. Breast, 2017, 32, 225-226.	2.2	1
15	Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. Journal of Clinical Oncology, 2016, 34, 4249-4255.	1.6	77
16	Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer. Breast Cancer Research and Treatment, 2015, 150, 605-611.	2.5	19
17	Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched case-control study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study.. Journal of Clinical Oncology, 2015, 33, 1520-1520.	1.6	0
18	Hype versus Hope: Metformin and Vitamin D as Anticancer Agents. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e69-e74.	3.8	2

#	ARTICLE	IF	CITATIONS
19	Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC).. Journal of Clinical Oncology, 2014, 32, 504-504.	1.6	1